Source:http://linkedlifedata.com/resource/pubmed/id/12899575
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2003-8-5
|
pubmed:abstractText |
The parasite Leishmania has been used for pioneering work to define T-cell subsets and cytokine patterns mediating susceptibility or resistance to infectious pathogens. This understanding has been essential for the development of a new generation of candidate vaccines for major diseases, such as leishmaniases themselves, tuberculosis and others. It is clear that effective vaccines can be developed through a combination of both antigen and adjuvant selection. Until recently, no adjuvants acceptable for use in human T-cell vaccines were available. However, one such adjuvant, monophosphoryl lipid A, has been shown to be safe and effective. Just as the understanding of T-cell responses has been necessary for the development of a new generation of vaccines, an understanding of signaling by antigen-presenting cells has been essential for adjuvant selection. A combination of antigens and an adjuvant that is effective at promoting durable T-helper 1 responses and is safe for human use comprise a promising vaccine candidate, Leish-111f. This vaccine has potential application in both the prevention and treatment of leishmaniasis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Protozoan,
http://linkedlifedata.com/resource/pubmed/chemical/Lipid A,
http://linkedlifedata.com/resource/pubmed/chemical/Protozoan Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/monophosphoryl lipid A
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1476-0584
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
2
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
239-52
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12899575-Adjuvants, Immunologic,
pubmed-meshheading:12899575-Animals,
pubmed-meshheading:12899575-Antigens, Protozoan,
pubmed-meshheading:12899575-Humans,
pubmed-meshheading:12899575-Leishmania,
pubmed-meshheading:12899575-Leishmaniasis,
pubmed-meshheading:12899575-Lipid A,
pubmed-meshheading:12899575-Mice,
pubmed-meshheading:12899575-Protozoan Vaccines,
pubmed-meshheading:12899575-T-Lymphocytes
|
pubmed:year |
2003
|
pubmed:articleTitle |
Development of a leishmaniasis vaccine: the importance of MPL.
|
pubmed:affiliation |
Corixa Corporation, Seattle, WA, USA.
|
pubmed:publicationType |
Journal Article,
Review
|